+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men's health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

  • Oct 02, 2024: Lilly Announces New $4.5 Billion Site - The Lilly Medicine Foundry - To Drive Innovation in Drug Production and Make Medicines for Clinical Trials
  • Sep 20, 2024: Federal Trade Commission Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
  • Sep 12, 2024: Lilly Expands Manufacturing Footprint in Ireland With $1.8 Billion Investment
  • Sep 09, 2024: Lilly Names Lucas Montarce as Executive Vice President and Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Eli Lilly and Co - Key Facts
  • Eli Lilly and Co - Key Employees
  • Eli Lilly and Co - Key Employee Biographies
  • Eli Lilly and Co - Major Products and Services
  • Eli Lilly and Co - History
  • Eli Lilly and Co - Company Statement
  • Eli Lilly and Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Eli Lilly and Co - Business Description
  • Product Category: Diabetes
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Other
  • Overview
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Other Foreign Countries
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Eli Lilly and Co - Corporate Strategy
  • Eli Lilly and Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Eli Lilly and Co - Strengths
  • Eli Lilly and Co - Weaknesses
  • Eli Lilly and Co - Opportunities
  • Eli Lilly and Co - Threats
  • Eli Lilly and Co - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Eli Lilly and Co, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Oct 02, 2024: Lilly Announces New $4.5 Billion Site - The Lilly Medicine Foundry - To Drive Innovation in Drug Production and Make Medicines for Clinical Trials
  • Sep 20, 2024: Federal Trade Commission Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
  • Sep 12, 2024: Lilly Expands Manufacturing Footprint in Ireland With $1.8 Billion Investment
  • Sep 09, 2024: Lilly Names Lucas Montarce as Executive Vice President and Chief Financial Officer
  • Sep 05, 2024: Lilly partners with Haya for lncRNA obesity target deal worth $1bn
  • Aug 16, 2024: Lilly Announces Retirement of Marschall S. Runge From Its Board of Directors
  • Aug 13, 2024: Lilly Opens State-Of-The-Art Research and Development Center in the Boston Seaport
  • Aug 08, 2024: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
  • Aug 01, 2024: AbCellera and Lilly broadens antibody discovery partnership
  • Jun 25, 2024: Lilly Collaborates with OpenAI to Discover Novel Medicines to Treat Drug-Resistant Bacteria
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Eli Lilly and Co, Key Facts
  • Eli Lilly and Co, Key Employees
  • Eli Lilly and Co, Key Employee Biographies
  • Eli Lilly and Co, Major Products and Services
  • Eli Lilly and Co, History
  • Eli Lilly and Co, Subsidiaries
  • Eli Lilly and Co, Joint Venture
  • Eli Lilly and Co, Key Competitors
  • Eli Lilly and Co, Ratios based on current share price
  • Eli Lilly and Co, Annual Ratios
  • Eli Lilly and Co, Interim Ratios
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Eli Lilly and Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Eli Lilly and Co, Performance Chart (2019 - 2023)
  • Eli Lilly and Co, Ratio Charts
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takeda Pharmaceutical Co Ltd
  • Heska Corp
  • Pfizer Inc
  • Novo Nordisk AS
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • Kiniksa Pharmaceuticals Ltd
  • Johnson & Johnson
  • Gilead Sciences Inc
  • Sanofi
  • Nymox Pharmaceutical Corp
  • GSK plc
  • Novartis AG
  • Merck & Co Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Baxter International Inc
  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd